Shots: Velabs and Alytas collaborated to jointly develop modulatory and functional Ab for a novel immune-based therapy against obesity utilizing Velabs’ microfluidic-based technology for rapid functional antibody screening Velabs to […]readmore
Tags : Agreement
Shots: Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of […]readmore
Shots: Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, and Uruguay. Helsinn to retain rights […]readmore
Shots: Immatics to get $75M up front and is also eligible to receive ~$505M as option exercise fee for each licensed product including development, regulatory & commercial milestone plus royalties […]readmore
Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma […]readmore
Shots: MSD enters into a research collaboration and exclusive license agreement for the discovery and development of undisclosed vaccine candidates utilizing Themis’ measles virus vector-based platform Themis to receive ~200M […]readmore
Shots: Innovent and Eli Lilly entered into a licensing agreement to develop & commercialize novel diabetic therapy, OXM3 in China The license agreement will strengthen Innovent’s diabetic portfolio with the […]readmore
Shots: Sobi to sell its US FDA’s Priority Review Voucher to AstraZeneca for $95M in cash. The PRV was acquired as part of the acquisition of the emapalumab from Novimmune […]readmore
Mylan to pay $5M up front in addition to $25M (according to 2018 deal), contingent payments ~$100M, ~$225M milestones on the achievement of specified clinical and regulatory milestones and royalties […]readmore
Shots: GAIA to receive royalties, milestone and financial compensation during the development phase. Orexo to get exclusive WW rights to commercialize DTx (OXD-01) and is responsible for the clinical development, […]readmore